Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06855498 · ClinicalTrials.gov registry record · Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
A Phase 3 study of Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06855498: Recruiting Phase 3 study of Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.
NCT06855498 is a Phase 3 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 600 participants, above the 130-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (362% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06855498, a Phase 3 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Primary Outcome
Adverse events either reported for the first time in this Protocol or any AE ongoing and defined as treatment-emergent from the parent Protocol.
Conditions Studied
Interventions
- DRUG povorcitinib
Study Locations (20)
California
- Investigative Site US076 - Fountain Valley
- Investigative Site US077 - Fremont
- Investigative Site US071 - Huntington Beach
- Investigative Site US020 - Laguna Niguel
- Investigative Site US036 - Los Angeles
- Investigative Site US067 - Los Angeles
- Investigative Site US060 - Northridge
- Investigative Site US037 - Oakland
- Investigative Site US089 - Santa Monica
- Investigative Site US080 - Sherman Oaks
Arizona
- Investigative Site US004 - Phoenix
- Investigative Site US047 - Scottsdale
- Investigative Site US124 - Scottsdale
- Investigative Site US115 - Tucson
Arkansas
- Investigative Site US113 - Fayetteville
- Investigative Site US045 - Fort Smith
- Investigative Site US009 - Rogers
Alabama
- Investigative Site US086 - Birmingham
- Investigative Site US098 - Montgomery
Florida
- Investigative Site US129 - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 3 |
What NCT06855498 shows while recruiting
NCT06855498 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 130-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (362% higher).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which povorcitinib is the first listed.
NCT06855498 names 20 study sites across 5 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06855498 about?
NCT06855498 is a clinical study titled "Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib". Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
What is the current status of trial NCT06855498?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-02-28. Estimated completion is 2028-02-28.
What conditions does trial NCT06855498 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT06855498?
The interventions under investigation include: povorcitinib (DRUG).
Who is sponsoring clinical trial NCT06855498?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06855498 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06855498's enrollment target sits among peer trials
600 2nd of 12 the highest of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
ACTIVE NOT RECRUITING · Phase 3
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
-
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI